Clinical Research Directory

Inclusion Criteria: * The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (\< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry \[IHC\] score \< 3, gene copy number not amplified) * TNBC patients who are previously untreated and enrolled in the prospective Institutional Review Board (IRB) approved clinical trial: 2014-0185 * Patients who are able to understand and give consent to participating in the study Exclusion Criteria: * Is pregnant (confirmed by the patient as imaging clinic standard of care) or nursing mother * Has lesions involving chest wall * Has known allergy to Tc99m sestamibi * Has known contraindications to MRI * Has contraindication to MRI contrast